Compared to conventional imaging techniques such as MRI, CT, or bone scintigraphy, PET imaging, particularly with PSMA-labeled tracers, offers superior sensitivity and specificity for detecting prostate cancer lesions, especially in biochemical recurrence or advanced disease [3,28]. This evidence concerns the gene FOLH1 and prostate carcinoma.